Main Uses and Therapeutic Role

Эсмия (ulipristal acetate) is a selective progesterone receptor modulator. It is primarily used for the management of uterine fibroids, which are non-cancerous growths that develop in or around the uterus. The medication is designed to address the symptoms associated with these growths and to reduce their size.

Treatment of Uterine Fibroids

The primary therapeutic application involves the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. This includes:

• Reduction of Heavy Bleeding: One of the main goals of treatment is the rapid control of excessive menstrual bleeding, which is a common symptom of fibroids.
• Volume Reduction: The medication acts directly on the fibroids to decrease their overall size and volume.
• Symptom Relief: By reducing the size of the growths and controlling bleeding, the treatment helps alleviate associated physical discomfort and pressure-related symptoms.

Benefits in Clinical Management

In the context of long-term management, the use of this medication may offer several clinical benefits:

• Pre-operative Preparation: It is frequently used to reduce the size of fibroids and stop bleeding before a patient undergoes surgical intervention. This can simplify the surgical procedure and allow for more conservative surgical options.
• Intermittent Management: For some patients, the medication may be used in repeated courses to provide long-term symptom control, potentially delaying or avoiding the need for surgery altogether.
• Improvement in Quality of Life: By addressing the physical symptoms of fibroids, the treatment aims to reduce the impact of the condition on daily activities and overall well-being.

Regulatory References

1. UK Medicines and Healthcare products Regulatory Agency Guidance

Eligibility Map: Who can and cannot use Эсмия (Ulipristal Acetate 5 mg) — Official Regulatory Information

Category	Regulatory Wording/Status
Populations for whom use is allowed (as stated in label):	Premenopausal adult women (ge 18 years) for intermittent treatment of moderate to severe symptoms of uterine fibroids [1.1].
Populations for whom use is not recommended (if applicable):	Patients with severe renal impairment (unless closely monitored) [1.1]. Women with severe asthma insufficiently controlled by oral glucocorticoids [1.3].
Populations for whom use is contraindicated:	Pregnancy and breastfeeding [1.1]. Patients with an underlying hepatic disorder [1.1]. Patients with known or suspected malignancies of the breast, uterus, cervix, or ovary [1.1].

---

Official Eligibility Statements

• The medicine is strictly authorized for premenopausal adult women ge 18 years [1.1, 1.6].
• Use is contraindicated in women with pre-existing conditions such as underlying hepatic disorder or cancers of the breast or reproductive organs [1.1, 1.2].
• Use is contraindicated in women who are pregnant or breastfeeding [1.1, 1.2].
• Eligibility is explicitly restricted to women when surgery is not suitable or has failed, with mandatory requirements for liver function monitoring [1.4, 3.2, 3.4].

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use this medicine by establishing premenopausal status as the sole approved population, while imposing absolute contraindications based on specific cancers, underlying hepatic disorder, pregnancy, and breastfeeding. Further restrictions limit use to a defined treatment context, specifically for patients whose surgical options are unavailable or unsuccessful, necessitating adherence to strict liver enzyme monitoring protocols [1.3, 3.4]. The safety and efficacy of the medicine are not established in the pediatric population [1.2, 1.3].

Interactions with other medicines and products

Ulipristal acetate (Эсмия) interactions are primarily governed by its metabolism and its pharmacological effect on the progesterone receptor.

---

Pharmacokinetic Interactions (Drug Exposure)

Ulipristal acetate is mainly metabolized by the CYP3A4 enzyme system. Regulatory labeling defines two main restrictions:

Interacting Agents	Official Regulatory Constraint
Strong/Moderate CYP3A4 Inducers (e.g., rifampin, phenytoin, St. John's Wort)	Contraindicated: These agents significantly decrease ulipristal exposure, potentially reducing effectiveness.
Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir)	Use with Caution: These agents can increase ulipristal exposure (AUC/Cmax).

---

Pharmacodynamic & Transport Interactions

Interacting Agents	Official Regulatory Constraint
Progestin-containing products (e.g., hormonal contraceptives)	Avoid/Contraindicated: May reduce the effectiveness of ulipristal due to receptor antagonism. The resumption of hormonal contraception is officially advised no sooner than 5 days after ulipristal intake.
P-glycoprotein (P-gp) Substrates (e.g., digoxin)	Use with Caution: Ulipristal may potentially increase the concentration of co-administered P-gp substrates.
Gastric pH Modifiers (e.g., PPIs, antacids)	No Clinically Relevant Interaction: Official data indicates these agents do not significantly affect ulipristal exposure.

---

Population-Specific Note: Use is officially contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) due to limited safety data related to the drug's metabolic clearance.

Эсмия, whose active pharmaceutical ingredient is ulipristal acetate, functions as a Selective Progesterone Receptor Modulator (SPRM). The molecule exhibits high-affinity, reversible binding to the intracellular progesterone receptor (PR), acting as both a partial agonist and antagonist in a tissue- and context-specific manner.

In the pituitary-ovarian axis, ulipristal acetate antagonizes the progesterone receptor, modulating the hypothalamic-pituitary-ovarian (HPO) axis. This interference results in the suppression or delay of the mid-cycle Luteinizing Hormone (LH) surge, which consequently prevents or postpones follicular rupture (ovulation).

In uterine tissue, the drug exerts a direct effect. It antagonizes the action of endogenous progesterone at the PR within uterine leiomyomas (fibroids), which are progesterone-dependent. This antagonism leads to intracellular consequences including the inhibition of cell proliferation and the induction of apoptosis (programmed cell death) in the fibroid cells. A distinct, reversible histological change, termed Progesterone Receptor Modulator Associated Endometrial Changes (PAEC), is also observed in the endometrium due to the selective PR modulation. These cellular actions result in the systemic physiological modulation of uterine size and blood loss.

Instruction Map: How to use Эсмия — Official Administration Guidelines

---

Administration scope

Detail	Instruction
Route of administration	Oral use.
Dosing schedule	One tablet of 5 mg (ulipristal acetate) per day.
Timing in relation to meals	May be taken with or without food.
Age-group administration rules	Established for use in women 18 years and older. No dose adjustment is recommended for mild or moderate renal or mild hepatic impairment.
Missed-dose rules	If a dose is missed by more than 12 hours, the dose must be skipped and the normal daily schedule resumed.

---

Instruction classifications (high-level)

Classification	Detail
Administration method type	Oral administration.
Frequency pattern	Once daily for the duration of the course.
Regulatory basis	Official product documentation and equivalent national pharmaceutical records.
Use-context constraints	Intermittent use pattern structured into time-limited courses (up to 3 months) separated by required treatment-free intervals.

---

Resulting procedural structure

Official step sequence:

• Start a new course during the first week of menstruation.
• Take one 5 mg tablet once daily orally, with or without food.
• Discontinue treatment after up to 3 months (12 weeks).
• Do not start a re-treatment course until the earliest of the first week of the second menstruation following the previous course.

Connection to the overall use protocol: The official usage protocol for Ulipristal Acetate structures therapy around precise cyclical timing, requiring that each once-daily, 5 mg oral course is both initiated and terminated according to specific menstrual markers. This cycle-dependent regimen defines the mandatory short-term duration of each treatment block and dictates the required treatment-free interval before re-initiation.

Recent Clinical Evidence

Overview of Studies

Clinical research has evaluated the effects of ulipristal acetate (Эсмия) in women diagnosed with uterine fibroids. Studies have explored the mechanism by which the drug may modulate progesterone receptors, a pathway that has been investigated for its role in uterine health and bleeding patterns. The research focused primarily on pre-operative treatment and management of heavy menstrual bleeding associated with fibroids.

Efficacy and Outcomes

Clinical trials primarily evaluated the drug's effect on reducing menstrual blood loss and the volume of uterine fibroids prior to surgical intervention. Studies reported observations regarding the cessation of uterine bleeding, which can lead to an improvement in iron stores and quality of life indicators for participants.

• Reduction in Bleeding: A majority of participants in large-scale trials were observed to experience a reduction in excessive menstrual bleeding during treatment cycles.
• Fibroid Volume: Research examined whether treatment resulted in a measurable reduction in the average size of the largest fibroids.

Safety and Monitoring

Studies have investigated the safety profile associated with the intermittent use of the drug. The trials included rigorous monitoring of endometrial changes and liver function, which is necessary due to the drug’s pharmacological class. Participants in the trials generally tolerated the treatment well, with frequently reported side effects being transient and including headache and mood changes. Research findings inform necessary monitoring protocols during the treatment course.

Key Studies & References

1. Royal College of Obstetricians and Gynaecologists (RCOG) Guideline: Management of Heavy Menstrual Bleeding

Common questions about Эсмия (FAQ)

---

Q: Does Эсмия treat all types of uterine fibroids?

Official product information describes the medicine as indicated for uterine fibroids causing moderate to severe symptoms. Regulatory texts focus on the symptoms of the condition rather than specifying or excluding different anatomical types of fibroids, such as intramural or subserosal.

Q: Can Эсмия be used for conditions other than uterine fibroids?

Regulatory documents state that the medicine is indicated solely for the intermittent treatment of moderate to severe symptoms caused by uterine fibroids in premenopausal women. Its purpose is restricted to this specific condition, particularly when other treatment options are not suitable or have failed.

Q: Is Эсмия the same as the emergency contraceptive pill with the same active ingredient?

No, the medicine for uterine fibroids is not the same as the emergency contraceptive pill, despite sharing the same active ingredient (ulipristal acetate). The product used for fibroids contains a different dose (5 mg) and is taken daily in an intermittent course, while the contraceptive is a single-dose 30 mg formulation.

Q: What does it mean if my doctor says surgery is "not suitable" for me to use Эсмия?

The official indication states that the medicine is restricted to women when surgical options or uterine fibroid embolization are not suitable or have failed. This restriction is part of the regulatory approval which defines the appropriate context for its use.

Q: Does Эсмия have any long-term effects on the uterus lining?

The medicine causes specific, reversible changes in the uterus lining known as PAEC (Progesterone Receptor Modulator Associated Endometrial Changes). Official data indicates these changes are expected and resolve spontaneously a few weeks to months after the treatment course is completed.

Q: Is it normal to have a headache or feel dizzy after starting Эсмия?

Official product information states that headache is a very common side effect reported by patients. Dizziness is also commonly reported as an adverse reaction in some regulatory documents.

Q: Does Эсмия cause changes in mood or anxiety?

Official product information lists mood disorders as a common side effect associated with the use of the medicine. Regulatory data also indicates that anxiety has been reported as an uncommon side effect.

Q: If a period stops, when can a patient expect it to return after finishing Эсмия?

The absence of menstruation (amenorrhea) is an expected effect of the medicine. According to official product information, the menstrual cycle generally resumes within four weeks after the treatment course has been completed.

Q: What is the expected duration of common side effects like headache or stomach pain?

Clinical evidence indicates that frequently reported side effects are generally mild to moderate and are often transient, meaning they resolve spontaneously. Regulatory labeling does not provide a specific duration in hours or days for these common side effects.

Q: Can taking other medications for liver disease affect the use of Эсмия?

Official documents state that the medicine is strictly contraindicated in women with an underlying hepatic disorder. For patients with moderate or severe liver impairment, use is generally not recommended unless they can be closely monitored by a healthcare professional.

Q: Is there specific research on using Эсмия for very large fibroids?

Research has focused on the reduction in volume of uterine fibroids and the average size of the largest fibroids in study participants. Regulatory summaries, however, do not define a specific size threshold to specify what constitutes a “very large” fibroid in the context of the clinical trials.

Q: Does Эсмия cure uterine fibroids permanently?

The medicine is officially indicated for the intermittent treatment of symptoms related to uterine fibroids. Because its effects on the endometrium are reversible and it is designed for intermittent use, regulatory documentation does not label the drug as a permanent cure for the condition.

Q: How long after stopping treatment do the effects of Эсмия last?

Studies indicate that the reduction in fibroid volume achieved during a course of treatment is generally maintained for a period after treatment is stopped. However, official product information does not define a definitive duration for how long these effects are maintained.

Q: What are the signs of liver damage I need to watch for while on Эсмия?

Regulatory health authorities describe that immediate discontinuation of the medicine and seeking medical attention is required if signs of liver injury are experienced. These symptoms include severe nausea, vomiting, dark urine, yellowing of the skin or eyes (jaundice), or severe pain in the upper right abdomen.

Q: What happens if a patient becomes pregnant while taking Эсмия?

The medicine is strictly contraindicated, meaning it must not be used, during pregnancy. If a patient becomes pregnant while taking the medicine, the regulatory requirement is for immediate discontinuation of the treatment and consultation with a healthcare provider.

Q: Why can’t women with unexplained vaginal bleeding use Эсмия?

Regulatory documents state that the medicine is contraindicated in women with genital bleeding of unknown cause. This is a safety measure to ensure that the bleeding is thoroughly investigated by a healthcare professional to rule out other underlying serious conditions.

Q: What should be done about spotting or unexpected bleeding while on Эсмия?

Official guidance describes that if an altered, persistent, or unexpected bleeding pattern occurs while taking the medicine, such as inter-menstrual bleeding or spotting, notification of a physician is required for investigation. This is necessary to exclude other underlying conditions.

Q: Can Эсмия cause hair loss or changes in skin condition like acne?

Regulatory product information lists acne as a common side effect associated with the use of the medicine. Hair loss, referred to as alopecia, is also listed as an uncommon side effect.

Q: Are there any rare but serious side effects reported with Эсмия besides liver issues?

Official safety data indicates that rare hypersensitivity reactions have been reported. These can include serious cases such as angioedema (swelling beneath the skin) and drug hypersensitivity with respiratory difficulty.

Q: How soon after starting treatment might a patient notice a reduction in symptoms?

Official clinical data indicates that the therapeutic action on bleeding usually begins quickly. A significant reduction in heavy menstrual blood loss or the onset of amenorrhea typically occurs within the first 10 days of starting treatment.

Q: Does grapefruit juice affect how Эсмия works in the body?

Regulatory information notes that grapefruit juice is classified as a moderate CYP3A4 inhibitor. Since the medicine is metabolized by this system, co-administration with grapefruit juice is generally not recommended as it may increase the level of the medicine in the body.

Q: Is the effectiveness of other medications I take reduced while I am on Эсмия?

Official drug interaction summaries state that the medicine may interfere with the action of hormonal contraceptive products that contain progestagen. This can consequently reduce the effectiveness of those contraceptive medicines.

Q: Were the clinical studies on Эсмия performed long-term?

Clinical studies for this medicine have examined the effects of repeated intermittent treatment. Research has investigated up to four intermittent courses, with each course lasting up to three months.

Q: What should a patient do if they vomit shortly after taking Эсмия?

According to regulatory guidance, if vomiting occurs less than three hours after taking the medicine, the dose may need to be repeated. Regulatory guidance states that a healthcare professional consultation is necessary for specific guidance in this situation.

Official Storage and Disposal Guidelines for Эсмия

Storage and disposal requirements for Эсмия (Ulipristal Acetate) are defined by regulatory documents, focusing on stability and compliance.

Storage Conditions

The primary requirement for storing the tablets is protection from light. To meet this rule, the blisters containing the medicine must be kept inside the original outer carton. No specific temperature range, such as refrigeration or freezing, is officially mandated for the product. The approved shelf life is 3 years.

Requirement	Status
Protection from Light	Mandatory (Store in outer carton)
Required Temperature	Not specified (Room temperature)
Shelf Life	3 Years

Disposal Instructions

Any unused or expired product must be discarded in accordance with local requirements. Official regulations do not provide specific environmental or hazardous waste instructions beyond adherence to established local procedures.